Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)
$2.31
+0.3100 ( +15.50% ) 331.8K
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Market Data
Open
$2.31
Previous close
$2.00
Volume
331.8K
Market cap
$145.74M
Day range
$2.01 - $2.33
52 week range
$1.05 - $2.86
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
8-k | 8K-related | 13 | Jun 14, 2024 |
4 | Insider transactions | 1 | May 14, 2024 |
4 | Insider transactions | 1 | May 08, 2024 |
4 | Insider transactions | 1 | May 08, 2024 |
10-q | Quarterly Reports | 74 | May 07, 2024 |